恩博帕拉提德的第一阶段临床试验,一种新的PTH受体1激动剂
Endocrine connections
|May 27, 2025
概括
恩博拉皮,一种新型治疗缺甲状腺症的新疗法,在健康志愿者中证明了安全性和有效性. 它有效调节血清水平,表明患者每日剂量的潜力.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 甲状腺功能低下症是一种罕见的内分泌疾病,其特点是甲状腺上腺激素 (PTH) 生产不足.
- 目前的治疗方法旨在使和酸盐水平正常化,但往往存在局限性.
- 恩博巴 (AZP-3601) 是一种新型的PTH受体1激动剂,用于治疗缺甲状腺症.
研究的目的:
- 为了评估恩博巴里德的安全性,耐受性,药理动力学 (PD) 和药理动力学 (PK).
- 评估恩博巴里德对和酸盐平衡的剂量依赖性影响.
- 为了确定恩博巴里德对持续控制血清的潜力.
主要方法:
- 这是一项随机,双盲,安慰剂控制的研究,涉及104名健康志愿者.
- 使用单次上升剂量 (SAD) 和多次上升剂量 (MAD) 队列.
- 药理学参数包括血清,,内源性PTH和尿路分泌.
主要成果:
- 没有报告任何严重的不良事件;所有都是轻度至中度的.
- 恩博巴里德显示血清的剂量依赖性增加和血清的减少.
- 尽管半衰期短,但药理动力学效应延长,在MAD队列中观察到持续的控制.
结论:
- 埃内博巴在健康志愿者中是安全的,并且耐受性很好.
- 该药物有效调节和酸盐水平,模仿PTH的作用.
- 恩博巴里德对持续的,每天一次的甲状腺功能低下症治疗有希望.
更多相关视频
07:53Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
Published on: December 10, 2010
18.1K
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.8K
相关概念视频
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials
9.3K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
9.3K
Preclinical Development: Overview
4.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
228
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
228
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
260
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
260
Drug Administration and Therapy Phases: Overview
781
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
781
